Novo Nordisk and Deep Apple Therapeutics have announced a research collaboration and exclusive worldwide license agreement to discover and develop oral small molecule therapeutics. The new drugs will be directed at a novel non-incretin GPCR target for cardiometabolic diseases, including obesity. Under the terms of the agreement, Deep Apple will discover and optimise compounds using […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!